Cladribine Falters, Biotech MS Candidates Move Up
By Catherine Shaffer
Thursday, March 3, 2011
A complete response letter caps the latest chapter in the troubled tale of EMD Serono Inc.'s cladribine tablets for relapsing and remitting multiple sclerosis (MS). The German company, an affiliate of Merck KGaA, has struggled to get the drug through the U.S. and European regulatory gauntlet, suffering setbacks nearly every step of the way.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.